Top

Inflammation Research

Published in:

01-08-2010 | Original Research Paper

Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam

Authors: Javeria Ali Hashmi, Kiran Yashpal, David W. Holdsworth, James L. Henry

Published in: Inflammation Research | Issue 8/2010

Abstract

Objective and design

The objective of this study was to determine the ability of meloxicam prophylaxis and therapy to blunt the effect of complete Freund’s adjuvant (CFA) induced monoarthritis.

Materials and methods

First the validity of this animal model was established by examining joint changes at multiple levels after injecting CFA into the tibio-tarsal joint. Next, meloxicam (5 mg/kg) or vehicle was administered on days 0–7 (prophylactic) and on days 7–16 (therapeutic) in separate groups of animals.

Results

The CFA-injected joint demonstrated hallmark histological and structural changes such as pannus formation, bone remodeling, cartilage erosion and immune cell infiltration. Both prophylactic and therapeutic treatment with meloxicam effectively reduced swelling (ankle circumference), oedema and extravasation of Evans blue dye in the affected joint. Moreover, meloxicam reduced loss in range of motion and also reduced mechanical stimulus evoked pain scores. Notably, these effects persisted after discontinuing drug treatment.

Conclusion

The present study provides a unique comparison of prophylactic versus therapeutic effects of meloxicam in the CFA-induced model of monoarthritis.

Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):1–12.PubMed

Sprangers MA, de Regt EB, Andries F, van Agt HM, Bijl RV, de Boer JB, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol. 2000;53(9):895–907.CrossRefPubMed

Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835–40.CrossRefPubMed

Uhlig T, Loge JH, Kristiansen IS, Kvien TK. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241–7.PubMed

Badley EM, Webster GK, Rasooly I. The impact of musculoskeletal disorders in the population: are they just aches and pains? Findings from the 1990 Ontario Health Survey. J Rheumatol. 1995;22(4):733–9.PubMed

Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol. 2002;14(2):121–6.CrossRefPubMed

Chorus AM, Miedema HS, Boonen A, Van Der LS. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis. 2003;62(12):1178–84.CrossRefPubMed

Sousa KH, Ryu E, Kwok OM, Cook SW, West SG. Development of a model to measure symptom status in persons living with rheumatoid arthritis. Nurs Res. 2007;56(6):434–40.CrossRefPubMed

Kalyoncu U, Dougados M, Daures JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2008;68:183–190.CrossRefPubMed

10.

Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–45.CrossRefPubMed

11.

Sokka T, Kankainen A, Hannonen P. Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis Rheum. 2000;43(2):386–9.CrossRefPubMed

12.

Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum. 1978;21(7):827–33.CrossRefPubMed

13.

Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29(5):305–20.CrossRefPubMed

14.

Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl. 1996;44:47–51.PubMed

15.

Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999;42(2):347–56.CrossRefPubMed

16.

Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, et al. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making. 2007;27(2):138–50.CrossRefPubMed

17.

Chen M, Boilard E, Nigrovic PA, Clark P, Xu D, Fitzgerald GA, et al. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis. Arthritis Rheum. 2008;58(5):1354–65.CrossRefPubMed

18.

Hernanz A, De ME, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol. 1993;32(1):31–5.CrossRefPubMed

19.

Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol. 1991;20(5):326–35.CrossRefPubMed

20.

Averill S, Inglis JJ, King VR, Thompson SW, Cafferty WB, Shortland PJ, et al. Reg-2 expression in dorsal root ganglion neurons after adjuvant-induced monoarthritis. Neuroscience. 2008;155(4):1227–36.CrossRefPubMed

21.

Bulling DG, Kelly D, Bond S, McQueen DS, Seckl JR. Adjuvant-induced joint inflammation causes very rapid transcription of beta-preprotachykinin and alpha-CGRP genes in innervating sensory ganglia. J Neurochem. 2001;77(2):372–82.CrossRefPubMed

22.

Dowd E, McQueen DS, Chessell IP, Humphrey PP. P2X receptor-mediated excitation of nociceptive afferents in the normal and arthritic rat knee joint. Br J Pharmacol. 1998;125(2):341–6.CrossRefPubMed

23.

Bar KJ, Natura G, Telleria-Diaz A, Teschner P, Vogel R, Vasquez E, et al. Changes in the effect of spinal prostaglandin E2 during inflammation: prostaglandin E (EP1–EP4) receptors in spinal nociceptive processing of input from the normal or inflamed knee joint. J Neurosci. 2004;24(3):642–51.CrossRefPubMed

24.

Fang M, Wang Y, Liu HX, Liu XS, Han JS. Decreased GDNF mRNA expression in dorsal spinal cord of unilateral arthritic rat. Neuroreport. 2000;11(4):737–41.CrossRefPubMed

25.

Sharif NR, Cahill CM, Ribeiro-da-Silva A, Menard HA, Henry JL. Remodelling of spinal nociceptive mechanisms in an animal model of monoarthritis. Eur J Neurosci. 2005;22(8):2005–15.CrossRef

26.

Djouhri L, Lawson SN. Increased conduction velocity of nociceptive primary afferent neurons during unilateral hindlimb inflammation in the anaesthetised guinea-pig. Neuroscience. 2001;102(3):669–79.CrossRefPubMed

27.

Djouhri L, Koutsikou S, Fang X, McMullan S, Lawson SN. Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J Neurosci. 2006;26(4):1281–92.CrossRefPubMed

28.

Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 1996;390(2):165–9.CrossRefPubMed

29.

MacDonald TM, Pettitt D, Lee FH, Schwartz JS. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology (Oxford) 2003 Nov;42 Suppl 3:iii3–10.

30.

Johnell K, Fastbom J. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study. Clin Drug Investig. 2008;28(11):687–95.CrossRefPubMed

31.

Laird JM, Herrero JF, Garcia de la RP, Cervero F. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: central and peripheral components. Inflamm Res. 1997;46(6):203–10.CrossRefPubMed

32.

Lam FF, Wong HH, Ng ES. Time course and substance P effects on the vascular and morphological changes in adjuvant-induced monoarthritic rats. Int Immunopharmacol. 2004;4(2):299–310.CrossRefPubMed

33.

Kumar VL, Roy S, Sehgal R, Padhy BM. A comparative study on the efficacy of rofecoxib in monoarticular arthritis induced by latex of Calotropis procera and Freund’s complete adjuvant. Inflammopharmacol. 2006;14(1–2):17–21.CrossRef

34.

Butler SH, Godefroy F, Besson JM, Weil-Fugazza J. A limited arthritic model for chronic pain studies in the rat. Pain. 1992;48(1):73–81.CrossRefPubMed

35.

Pitcher GM, Ritchie J, Henry JL. Paw withdrawal threshold in the von Frey hair test is influenced by the surface on which the rat stands. J Neurosci Methods. 1999;87(2):185–93.CrossRefPubMed

36.

Pearson CM. Experimental joint disease observations on adjuvant-induced arthritis. J Chronic Dis. 1963;16:863–74.CrossRefPubMed

37.

Vermeirsch H, Biermans R, Salmon PL, Meert TF. Evaluation of pain behavior and bone destruction in two arthritic models in guinea pig and rat. Pharmacol Biochem Behav. 2007;87(3):349–59.CrossRefPubMed

38.

Wilson AW, Medhurst SJ, Dixon CI, Bontoft NC, Winyard LA, Brackenborough KT, et al. An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. Eur J Pain. 2006;10(6):537–49.CrossRefPubMed

39.

Cannon GW, Openshaw S, Clayton F, Sawitzke AD, Griffiths MM. Adjuvant arthritis in rats: susceptibility to arthritis induced by Mycobacterium butyricum and Mycobacterium tuberculosis. Transplant Proc. 1999;31(3):1590–1.CrossRefPubMed

40.

Cannon GW, Woods ML, Clayton F, Griffiths MM. Induction of arthritis in DA rats by incomplete Freund’s adjuvant. J Rheumatol. 1993;20(1):7–11.PubMed

41.

Issekutz AC, Mu JY, Liu G, Melrose J, Berg EL. E-selectin, but not P-selectin, is required for development of adjuvant-induced arthritis in the rat. Arthritis Rheum. 2001;44(6):1428–37.CrossRefPubMed

42.

Haak T, Delverdier M, Amardeilh MF, Oswald IP, Toutain PL. Pathologic study of an experimental canine arthritis induced with Complete Freund’s Adjuvant. Clin Exp Rheumatol. 1996;14(6):633–41.PubMed

43.

Weinblatt ME. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003 Nov;62 Suppl 2:ii94–ii96.

44.

Holmdahl R, Lorentzen JC, Lu S, Olofsson P, Wester L, Holmberg J, et al. Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev. 2001;184:184–202.CrossRefPubMed

45.

Calvino B, Crepon-Bernard MO, Le BD. Parallel clinical and behavioural studies of adjuvant-induced arthritis in the rat: possible relationship with ‘chronic pain’. Behav Brain Res. 1987;24(1):11–29.CrossRefPubMed

46.

Godefroy F, Weil-Fugazza J, Besson JM. Complex temporal changes in 5-hydroxytryptamine synthesis in the central nervous system induced by experimental polyarthritis in the rat. Pain. 1987;28(2):223–38.CrossRefPubMed

47.

Reiber H, Suckling AJ, Rumsby MG. The effect of Freund’s adjuvants on blood–cerebrospinal fluid barrier permeability. J Neurol Sci. 1984;63(1):55–61.CrossRefPubMed

48.

Millan MJ, Czlonkowski A, Morris B, Stein C, Arendt R, Huber A, et al. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain. 1988;35(3):299–312.CrossRefPubMed

49.

Stein C, Millan MJ, Herz A. Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav. 1988;31(2):445–51.CrossRef

50.

Donaldson LF, Seckl JR, McQueen DS. A discrete adjuvant-induced monoarthritis in the rat: effects of adjuvant dose. J Neurosci Methods. 1993;49(1–2):5–10.CrossRefPubMed

51.

Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, et al. Allodynia and hyperalgesia in adjuvant-induced arthritic rats: time course of progression and efficacy of analgesics. J Pharmacol Exp Ther. 2003;306(2):490–7.CrossRefPubMed

52.

Inglis JJ, Notley CA, Essex D, Wilson AW, Feldmann M, Anand P, et al. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum. 2007;56(12):4015–23.CrossRefPubMed

53.

Lu Y, McNearney TA, Wilson SP, Yeomans DC, Westlund KN. Joint capsule treatment with enkephalin-encoding HSV-1 recombinant vector reduces inflammatory damage and behavioural sequelae in rat CFA monoarthritis. Eur J Neurosci. 2008;27(5):1153–65.CrossRefPubMed

54.

Conaghan PG, O’Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum. 2003;48(1):64–71.CrossRefPubMed

55.

Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002 Nov;61 Suppl 2:ii84–ii86.

56.

Halla JT, Hardin JG, Fallahi S. The nature of the onset of rheumatoid arthritis: a reassessment. Rheumatol Int. 1987;7(4):169–71.CrossRefPubMed

57.

Halla JT, Hirsch V. Monoarthritis as the presenting manifestation of localized Ewing’s sarcoma in an older patient. J Rheumatol. 1987;14(3):628–31.PubMed

58.

Masi AT. Articular patterns in the early course of rheumatoid arthritis. Am J Med. 1983;75(6A):16–26.CrossRefPubMed

59.

Hazes JM. Determinants of physical function in rheumatoid arthritis: association with the disease process. Rheumatology (Oxford) 2003 May;42 Suppl 2:ii17–ii21.

60.

Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995;44(10):423–33.CrossRefPubMed

61.

Furst DE, Kolba KS, Fleischmann R, Silverfield J, Greenwald M, Roth S, et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol. 2002;29(3):436–46.PubMed

62.

Omote K, Kawamata T, Nakayama Y, Yamamoto H, Kawamata M, Namiki A. Effects of a novel selective agonist for prostaglandin receptor subtype EP4 on hyperalgesia and inflammation in monoarthritic model. Anesthesiology. 2002;97(1):170–6.CrossRefPubMed

Title: Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam
Authors: Javeria Ali Hashmi
Kiran Yashpal
David W. Holdsworth
James L. Henry
Publication date: 01-08-2010
Publisher: SP Birkhäuser Verlag Basel
Published in: Inflammation Research / Issue 8/2010
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-010-0179-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective and design

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2010

Inhibition of degranulation and cytokine production in bone marrow-derived mast cells by hydrolyzed rice bran

Urinary trypsin inhibitor suppresses excessive generation of superoxide anion radical, systemic inflammation, oxidative stress, and endothelial injury in endotoxemic rats

Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock

Anti-α4β1 integrin antibody induces receptor internalization and does not impair the function of circulating neutrophilic leukocytes

Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress

C5a promotes migration, proliferation, and vessel formation in endothelial cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials